BioSpace News Archive

Cyclo Therapeutics, Inc. announced that Sharon H. Hrynkow, Ph.D., its Chief Scientific Officer and Senior Vice President for Medical Affairs, has been appointed to the President’s Council of Advisors on Science and Technology On October 22, President Donald J. Trump signed an executive order re-chartering PCAST and announced the first seven members, including Dr. Hrynkow.

XBiotech Inc. announced that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating bermekimab in patients with moderate to severe Hidradenitis Suppurativa The multi-center, international study will enroll approximately 150 patients into three arms: two bermekimab dosing regimens versus a placebo arm over sixteen weeks of therapy.

RAPT Therapeutics, Inc. reported the initiation of its first-in-human Phase 1 clinical trial for RPT193, an orally-administered small molecule CCR4 antagonist that is designed to selectively inhibit the migration of type 2 T helper cells, or Th2 cells, into allergically-inflamed tissues.

Abacus Health Products, Inc. announced that it has received approval from the Depository Trust Company to make the Company’s subordinate voting shares eligible to be electronically cleared and settled through DTC.

Breast Cancer Awareness Month may be winding down, but Patricia Levett’s battle against metastatic breast cancer continues. This week, the 48-year-old grandmother from Clayton, North Carolina, will embark on her 27th Miracle Flight to the ongoing medical treatment that’s saving her life.

Nolato AB has published its interim report for the third quarter of 2019.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, presented additional new data from Cohort 1 of its ongoing Phase 2/3 randomized, double-blind, placebo-controlled clinical study (iNO-PF) of INOpulse® for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) as a late-breaking oral presentation at the American College of Chest Physicians (CHEST) 2019 Annual Meeting in New Orleans.

HealthEC, LLC, a 2019 Best in KLAS provider of Population Health Management solutions, announced that the firm helped its Accountable Care Organization clients enrolled in the Medicare Shared Savings Program achieve a combined $64.9 million in savings for the 2018 performance year.

Yield10 Bioscience, Inc. announced that it has signed a research agreement with Boise, Idaho-based J. R. Simplot Company, to evaluate three novel yield traits in potato.

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will report third quarter 2019 financial results on Tuesday, October 29, 2019 after the market close.